Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells $399,300.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the completion of the sale, the insider now directly owns 1,034,015 shares of the company’s stock, valued at $13,762,739.65. This represents a 2.82 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $12.75 on Friday. Day One Biopharmaceuticals, Inc. has a one year low of $11.94 and a one year high of $18.07. The firm’s 50 day moving average price is $14.19 and its 200-day moving average price is $14.04. The firm has a market cap of $1.29 billion, a P/E ratio of -12.38 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The firm had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same quarter last year, the company earned ($0.54) earnings per share. As a group, research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new stake in Day One Biopharmaceuticals during the third quarter worth about $825,000. First Turn Management LLC purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter worth about $13,204,000. Algert Global LLC lifted its stake in Day One Biopharmaceuticals by 248.8% during the third quarter. Algert Global LLC now owns 71,487 shares of the company’s stock worth $996,000 after purchasing an additional 50,990 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Day One Biopharmaceuticals by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock worth $7,069,000 after buying an additional 64,700 shares during the last quarter. Finally, Vestal Point Capital LP lifted its position in Day One Biopharmaceuticals by 100.0% in the third quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock valued at $34,825,000 after acquiring an additional 1,250,000 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DAWN. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.